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HCV (STAT-C), wherein orally administered small molecules
can provide targeted activity at speciﬁc points in the viral
life cycle. The ability to target speciﬁc steps of repli-
cation is apparent in the myriad of novel therapies in
research, such as protease inhibitors, nucleoside and non-
nucleoside polymerase inhibitors, glucosidase Inhibitors,
inosine monophosphate dehyrogenase (IMPDH) inhibitors,
and immune modulators (Interferons and their inducers,
toll-like receptor analogues, therapeutic vaccines). Combi-
nation therapies with new small molecules and peg-INF with
or without ribavirin are currently being evaluated. One of
the challenges of STAT-C therapy would be the prevention of
the evolution of drug resistance while enhancing tolerabil-
ity, decreasing treatment duration, and ultimately achieving
higher sustained virologic response rates.
doi:10.1016/j.ijid.2008.05.090
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Treatment of Hepatitis C in the HIV-Infected Subject
N. Terrault
University of California San Francisco, San Francisco, CA,
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Liver complications have emerged as an important cause of
hospitalization and mortality among HIV-infected persons.1
Anti-HCV treatment offers the opportunity to eradicate HCV,
reduce the risk of disease progression and reduce liver-
related deaths. These beneﬁts are signiﬁcant and provide
the justiﬁcation for consideration of HCV treatment in every
HIV-HCV coinfected patient. However, since treatment is not
uniformly effective and is associated with side effects in the
majority of treated patients, the decision to proceed with
treatment requires a careful weighing of risk and beneﬁts
for each patient.
Patients should be on a stable ART regimen for at least
3 months prior to starting HCV treatment. Didanosine (DDI)
is absolutely contraindicated due to high risk of toxicity.2
Stavudine (D4T) and abacavir are relative contraindicated
due to interactions with ribavirin. AZT increases the risk of
anemia and should be avoided if possible.
The treatment of choice is peginterferon alfa (peg-IFN)
and weight-based ribavirin (1000mg daily if <75 kg and
1200mg daily if >75 kg).3 Weight-based ribavirin is recom-
mended for all genotypes, due to the higher rate of relapse
in HCV-HIV coinfected patients compared with HCV monoin-
fected patients. The dose of peginterferon alfa-2a is 180 ug
weekly and of peginterferon alfa-2b is 1.5 ug/kg weekly. The
duration of treatment is 24—48 weeks for genotypes 2 and
3 and 48—72 weeks for genotype 1, 4—6, with the time to
loss of HCV determining the length of treatment. Early viral
kinetics strongly inﬂuences duration of therapy. Shorter
duration may be a consideration in patients achieving a
rapid virologic response (RVR), deﬁned as undetectable HCV
RNA at week 4 of treatment. Longer duration therapy (up to
72 weeks) is a strong consideration in ‘‘slow responders’’.
The most consistently identiﬁed pre-treatment predictors
of SVR are HCV viral load and HCV genotype.4—7 Adherence
is an important factor in achieving SVR in HCV-monoinfected
patients but data in coinfected patients is more
limited.
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Patients labeled as non-responders need to be carefully
valuated to identify those that may beneﬁt from retreat-
ent using optimal doses and duration of current therapies.
he available data indicate that subjects who failed a prior
ourse of suboptimal therapy may achieve SVR but at rates
ower than treatment-naive patients.8 Overall, the chance
VR in previously treated patients is dependent upon the
fﬁcacy of the previous tried regimen.
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etabolic Abnormalities in HIV Infection
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Virginia Commonwealth University, Richmond, VA, USA
IV infected subjects often have a multitude of metabolic
efects. The clinical outcomes associated with these
bnormalities include lipodystrophy, insulin resistance, dys-
ipidemia, nonalcoholic fatty liver disease, accelerated
therosclerosis with both coronary artery disease (CAD)
nd peripheral vascular disease. The development of these
omplications reﬂect a complex interaction between the
atient, the HIV virus, other concomitant infections and
AART therapy. The seriousness of these complications is
nderscored by the rising mortality from non-HIV related
auses in infected subjects. This is particularly important
n males >55 yrs of age where CAD is the leading cause
f death. Subjects with HIV infection are at increased risk
or myocardial infarction and this risk is related to the
se of protease inhibitors (PI). It is however important to
ote that conventional risk factors e.g. smoking are more
mportant determinants of cardiovascular outcomes rather
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han the nature of antiretroviral therapy. It is proposed that
hanges in adipocyte biology drive these metabolic abnor-
alities. PIs inhibit CRABP-1 which is required for PPAR-g
n adipocyte differentiation factor. They also cause mito-
hondrial injury. Changes in adipocyte function have also
een noted in the absence of PI usage. These lead to either
ipoatrophy or lipohypertrophy or differential expression
f these phenotypes in the same subject. Lipoatrophy is
ssociated wth leptin deﬁciency and can be corrected by
eptin. Both lipoatrophy and lipohypertrophy are associated
ith insulin resistance. HIV infected subjects have increased
ipolysis secondary to insulin resistance. This is associated
ith high free fatty acid levels, impaired metabolic clear-
nce of glucose and hyperinsulinemia. These changes lead to
he development of nonalcoholic fatty liver disease (NAFLD).
AFLD accelerates progression to cirrhosis in those co-
nfected with hepatitis C, promotes resistance to anti-HCV
herapy, increased cholesterol production and increased
redeliction for CAD. PIs increased de novo lipogenesis
nd also increased HMG CoA reductase while decreasing
yp7A activity which normally converts cholesterol to bile
cids. Dyslipidemia results from both increased lipolysis,
ecreased clearance of triglycerides and increased choles-
erol production. The development of insulin resistance also
eads to activation of the innate immune system and an
cute phase reaction which creates a systemic proinﬂam-
atory, proﬁbrotic state and may activate endothelial cells.
ndothelial injury and hyperlipidemia lead to atherosclero-
is. PIs block metabolism of mature SREBP-1c and increase
ts half life thereby increasing the levels of its target CD36.
D36 is expressed on macrophages and promotes cholesterol
nd lipid uptake thereby creating foam cells and promoting
therosclerosis. To protect subjects from these, the car-
iovascular risk can be calculated from Framngham and
IV speciﬁc scores. The target LDL cholesterol for those
ith low risk (<10% over 10 yrs) is 195mg/dl while that for
oderate risk (10—20%) is 155mg/dl and high risk (>20%)
s 105mg/dl. This is accomplished by attention to tradi-
ional risk factors, diet and exercise as well as careful
election of HAART. NNRTI have the lowest while PI have
he highest metabolic impact. In those with dyslipidemia,
tatins and ﬁbrates are ﬁrst line therapy. Lovastatin and Sim-
astatin are contraindicated due to drug-drug interactions
ith HAART. It is important to maintain viral suppression
hile modulating HAART for dyslipidemia because fail-
re to keep the virus suppressed increases the risk of
ortality.
oi:10.1016/j.ijid.2008.05.092
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enome Analysis
.C. Darby
Liverpool School of Tropical Medicine, Liverpool, United
ingdom
crub typhus is caused by the obligate intracellular rick-
ttsia Orientia tsutsugamushi (previously called Rickettsia
sutsugamushi). The bacterium is maternally inherited in
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rombicuid mites and transmitted to humans by feeding
arvae. Orientia is a member of the Rickettsiales, a genet-
cally diverse group of the alpha-Proteobacteria, include
ajor mammalian pathogens, such as the agents of epi-
emic typhus, scrub typhus, ehrlichioses and heartwater
isease.
Sequenced genomes of this bacterial order have provided
xciting insights into reductive genome evolution, anti-
enic variation and host cell manipulation. The 2,127,051-bp
enome of the Boryong strain, which represents the most
ighly repeated bacterial genome sequenced to date. The
epeat density of the scrub typhus pathogen is 200-fold
igher than that of its close relative Rickettsia prowazekii,
he agent of epidemic typhus. A total of 359 tra genes
or components of conjugative type IV secretion systems
ere identiﬁed at 79 sites in the genome. Results suggest
ntragenomic duplications or multiple integrations of a mas-
ively proliferating conjugative transfer system. Diversifying
election on host-cell interaction genes along with repeated
opulation bottlenecks may drive rare genome variants to
xation, thereby short-circuiting selection for low complex-
ty in bacterial genomes.
oi:10.1016/j.ijid.2008.05.093
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enetic Variability of Orientia tsutsugamushi
.E. Fournier
Unité de Recherche sur les Maladies Infectieuses et Tropi-
ales Emergentes, CNRS-IRD UMR6236, Marseille, France
rientia tsutsugamushi, the agent of the reemerging dis-
ase scrub typhus, remains a puzzling microorganism. This
lpha proteobacterium, vectorized by thrombiculid mites,
as a complex genome containing an exceptionally high
epeat density likely resulting from duplication and genome
ecombination events. It also exhibits a great antigenic
iversity, with more than 30 serotypes currently identi-
ed, and a geographical speciﬁcity of strain distribution.
he genetic diversity of O. tsutsugamushi, which is tra-
uced by differences in mortality rates ranging from <1%
o 50%, has been the subject of few studies. Most genetic
nalyses of the population structure of O. tsutsugamushi
ere based on the study of genes encoding surface-exposed
ntigens recognized by the immune response of patients.
f these, the 56-kDa protein-encoding gene, unique to O.
sutsugamushi, has been the most extensively studied, rep-
esenting 70% of all gene sequences available in GenBank
or this species. Phylogenetic studies based on this gene
dentiﬁed 6 main clusters (Gilliam, Karp, Kato, Kawazaki,
uroki, Saitama) but it is likely that more clusters will be
escribed as highlighted by recent studies. When applying
he taxonomic criteria used for prokaryotes, the 16S rRNA
ucleotide divergence within the O. tsutsugamushi species,
s high as 4%, would justify the classiﬁcation of its isolates
n more than one species. In addition, to date, there is no
enotyping method that would allow tracing O. tsutsuga-
ushi at the strain level. Such a tool seems essential given
he emergence of antibiotic resistant strains. As a conse-
uence, further studies to understand the genetic variability
f O. tsutsugamushi are needed and may be performed
